Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1519670 (
tumor angiogenesis
)
6,052
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bone-marrow mesenchymal stem cells (BMSCs) have been used for systemic delivery of therapeutic genes to solid tumors. However, the optimal treatment time post-BMSC implantation and the assessment of the long-term fate of therapeutic BMSCs post-tumor treatment are critical if such promising therapies are to be translated into clinical practice. An efficient BMSC-based therapeutic strategy has been developed that simultaneously allows killing of tumor cells, inhibiting of
tumor angiogenesis
, and assessment and eradication of implanted BMSCs after treatment of glioblastoma. BMSCs were engineered to co-express the angiogenesis inhibitor kringle 5 (K5) of human
plasminogen
, under the control of the cytomegalovirus promoter (CMV) and the human sodium-iodide symporter (NIS), involved in uptake of radioisotopes, under the control of early growth response factor 1 (Egr1), a radiation-activated promoter. A significant decrease in tumor growth and
tumor angiogenesis
and a subsequent increase in survival were observed when mice bearing glioblastoma were treated with
188
Re post-therapeutic intravenous BMSC implantation. Furthermore, the systemic administration of
188
Re post-tumor treatment selectively eliminated therapeutic BMSCs expressing NIS, which was monitored in real time by
125
I micro single photon emission computed tomography/computed tomography imaging. Meanwhile, the Egr1 promoter induced a
188
Re radiation positive feedback effect absorbed by NIS. After intravenous BMSC implantation, BMSCs levels in the tumor and lung both peaked on day 10 and decreased to the lowest levels on days 24 and 17, respectively. These findings suggest that day 17 post-BMSC implantation could be an optimal time for
188
Re treatment. These results provide a new adjuvant therapy mediated by BMSCs for glioblastoma treatment.
...
PMID:Bone Marrow-Derived Mesenchymal Stem Cell-Mediated Dual-Gene Therapy for Glioblastoma. 2999 89
Prostate cancer (PCa) is the second most diagnosed cancer in Western male population. In this study, we insert mK5 (the mutational kringle5 of human
plasminogen
) into a DD3-promoted (differential display code 3) oncolytic adenovirus to construct OncoAd.mK5.DD3. E1A.dE1B, briefly, O
Ad
.DD3.mK5. DD3 is one of the most prostate cancer specific promoters which can transcriptionally control adenoviral replication. mK5 has been proved to be able to inhibit the
tumor angiogenesis
and inhibit cell proliferation. Our results suggested that targeting PCa with O
Ad
.DD3.mK5 elicited strong antitumor effect.
...
PMID:Prostate Cancer-Specific of DD3-driven Oncolytic Virus-harboring mK5 Gene. 3061 90
<< Previous
1
2
3
4
5
